Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3

Research output: Contribution to journalArticle

2 Citations (Scopus)
220 Downloads (Pure)

Abstract

Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5%) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6%) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23% (95% confidence interval=5-37%). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.Molecular Psychiatry advance online publication, 25 July 2017; doi:10.1038/mp.2017.152.

Original languageEnglish
Pages (from-to)1825-1829
Number of pages5
JournalMolecular Psychiatry
Volume23
Issue number8
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Somatomedins
Dementia
Insulin-Like Growth Factor Binding Proteins
Coronary Disease
Psychiatry
Longitudinal Studies
Publications
Blood Proteins
Cell Survival
Body Mass Index
Cross-Sectional Studies
Smoking
Stroke
Cell Proliferation
Confidence Intervals
Hypertension
Brain
Cognitive Dysfunction
Proteins

Cite this

@article{20fc345a2b64483093754b80dd2bb52a,
title = "Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3",
abstract = "Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5{\%}) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6{\%}) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23{\%} (95{\%} confidence interval=5-37{\%}). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.Molecular Psychiatry advance online publication, 25 July 2017; doi:10.1038/mp.2017.152.",
keywords = "Journal Article",
author = "Almeida, {O P} and Hankey, {G J} and Yeap, {B B} and {Paul Chubb}, {S A} and J Gollege and L Flicker",
year = "2018",
month = "8",
doi = "10.1038/mp.2017.152",
language = "English",
volume = "23",
pages = "1825--1829",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group - Macmillan Publishers",
number = "8",

}

TY - JOUR

T1 - Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3

AU - Almeida, O P

AU - Hankey, G J

AU - Yeap, B B

AU - Paul Chubb, S A

AU - Gollege, J

AU - Flicker, L

PY - 2018/8

Y1 - 2018/8

N2 - Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5%) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6%) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23% (95% confidence interval=5-37%). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.Molecular Psychiatry advance online publication, 25 July 2017; doi:10.1038/mp.2017.152.

AB - Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5%) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6%) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23% (95% confidence interval=5-37%). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.Molecular Psychiatry advance online publication, 25 July 2017; doi:10.1038/mp.2017.152.

KW - Journal Article

U2 - 10.1038/mp.2017.152

DO - 10.1038/mp.2017.152

M3 - Article

VL - 23

SP - 1825

EP - 1829

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 8

ER -